Implementation of Porter Dimond Theory in Beximco

depict On Implementation of doorman diamond scheme in Beximco pharmaceutics Ltd Course Title world(prenominal) handicraft Course formulaBUS-302 Semester F all told12 PREPARED FOR Gouranga Chandra Debnath Senior LECTURER, De ramifyment of Business arrangement FACULTY OF BUSINESS & ECONOMICS (DIU) PREPARED BY Esteak Ahmed ID 091-11-809 Contents Chapter 12 Introduction2 Background of the Report2 1. 5 Overview of the doorman diamond system4 Chapter 26 2. 2 loaded Structure, Strategy, and Rivalry6 2. 3 ingest condition8 2. 4 Factors of Endowments ( both(prenominal) canonic and advance)10 2. Related and supporting attention12 2. 7 boilers suit analysis of the cordial club position originationd on porters diamond13 Log Frame14 Chapter 316 Conclusion16 3. 2 Recommendations16 3. 3 References16 Chapter 1 In an contract to surmount and perfect the trade system more than inquiry has been conducted and many theories has been proposed. Inter commonwealthal Trade speculat ion provides expla states for the pattern of external trade and the dissemination of the gains from trade. In an attempt to master and perfect the trade system many research has been conducted and many theories has been proposed. internationalist Trade Theory provides explanations for the pattern of international trade and the distri only ifion of the gains from trade. Introduction Background of the Report For thousands of twelvemonths humans argon affect in trade and always act to perfect this system. In an attempt to master and perfect the trade system many research has been conducted and many theories has been proposed. International trade surmisal provides explanations for the pattern of international trade and the distri preciselyion of the gains from trade.The theory convinces to the highest degree economists of the benefits of vainglorious trade. But many non-economists oppose liberal trade. Opponents include near who may attain encountered trade theory but neverth eless fall prey to fallacious reasoning. Porter diamond theory is an attempt of Professor Porter to explain the app bent relationship of international trade and former(a) components of a coun discover. Appargonntly pharmaceutical sector is technologically the most developed manufacturing industries in Bangladesh and the threesome largest industry in price of part to giving medications revenue.Porter Diamond theory support be implemented to a company of this sector to under(a) prevail the prospects, potentials, and problems of this sector. 1. 1 conception Of The Report The purpose of the report is to implement the porter diamond theory in the Beximco Pharmaceuticals Ltd guild of Bangladesh and to understand the problems, prospects and potential of this company. 1. 3 Methodology secondary coil data atomic calculate 18 use to analyze the implementation of the Porter Diamond Theory. 1. 4 Objective of the study The objectives of this study atomic number 18- * To find o ut whether all the element of Porters diamond are available in the company. To find out our companys current condition in the foodstuff and overly the opportunities and prospects. * Porter Diamond Theory is the go of an intensifier research conducted by Michael Porter and his team on century industries of 10 nations. For Porter the essential task was to explain why a nation achieves international success in a particular industry. Pharmaceutical industry contributes the 1% of the do GDP of Bangladesh. Porter Diamond Theory is the result of an intensifier research conducted by Michael Porter and his team on century industries of 10 nations.For Porter the essential task was to explain why a nation achieves international success in a particular industry. Pharmaceutical industry contributes the 1% of the aggregate GDP of Bangladesh. To analyze the current smirch of the rivals * To discuss the fill condition & guest base 1. 5 Overview of the Porter Diamond Theory Porter Diamond Theory is a installation of Michael Porter of the Harvard Business School. In 1990 he published the result of an intensive research effort that attempted to determine why some nations imitate and other fail in international completions.Porter and his team looked at 100 industries of 10 nations. Like the work of new trade theorists, Porters work was determined by a belief that the existing theories of international theory told the one-half of the story. For Porter the essential task was to explain why a nation achieves international success in a particular industry. Porter argues that four-spot broad attributes promote or impede the creation of competitive advantage. These attributes are * Factor of Endowments * Demand Condition * Relating and Supportive Industries. * plastered strategy, social structure, and rivalry.Porter maintains twain additive variables that can influence international business * Government * Chance 1. 6 Overview of the Pharmaceutical Industry in Bangl adesh Pharmaceutical sector is technologically the most developed manufacturing industries in Bangladesh and the third largest industry in terms of contribution to governments revenue. The industry contributes about 1% of the total GDP. there are about 250 licensed pharmaceutical manufacturers in the country however, presently a little over 100 companies are in operation.It is highly concentrated as top 20 companies produce 85% of the revenue. jibe to IMS, a US- found trade research firm, the retail merchandise size is estimated to be around BDT 84 billion as on 2011. Bangladesh pharmaceutical companied steering primarily on mark generic final groomings, mostly exploitation imported APIs (Active Pharmaceuticals Ingredient). brand generics are a category of drugs, including prescription drug produces, that are either novel dosage forms of off-patent convergences produced by a manufacturer that is non the originator of the olecule, or a molecule copy of an off-patent pro duct with a trade name. About 85% of the drugs sold in Bangladesh are generics and 15% are patented drugs the structure differs significantly from the international market. Branded generic drugs represent about 25% years. The success of the pharmaceutical industry in Bangladesh can be defined by the Porter Diamond Theory. Bangladesh manufactures about 450 generic drugs for 5,300 registered brands which have 8,300 different forms of dosages and strengths.These include a dewy-eyed range of products from anti-ulcerates, flour quinolones, anti-rheumatic non-steroid drugs, non-narcotic analgesics, antihistamines, and oral anti-diabetic drugs. near larger firms have overly started producing anti-cancer and anti-retroviral drugs. Domestic manufacturers account for 97% of the drug gross revenue in the local anaesthetic anesthetic market while the remaining 3% are imported. This is a masterly turnaround over from two/three decades back when imports are a complete turnaround over fr om two/three decades back when imports used to dominate the market.The imported drugs include essential live saving drugs and other high prize drugs. The ratio will further increase in favor of the local production as some of the big players are poised to manufacture these high quality drugs in-house in the future. 1. 7 Overview of the Company Beximco Pharmaceutical particular(a) (BPL) is one of the largest pharmaceuticals company in Bangladesh. Beximco Pharma was founded in 1976 and started operations in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of USA.It has immediately big(a) to become a leading pharmaceutical company in Bangladesh, and it supplies more than 10% of countrys total medicinal needs. Today Beximco Pharma manufactures and markets its cause branded generics for several diseases including AIDS, cancer, asthma, hypertension, and diabetes for both national and international markets. The company owns and work outs modernph armaceutical factories mainly in Bangladesh and as well has a separate division to operate a modern chemical factory which produces and sells basic chemical products. It also has divisions to produce and sell agro vet and pesticide products.Chapter 2 2. 1 Implementation Of the Theory As we said forward we studied our company based on Porters diamond which include fourinternal factors which are- 1. unfluctuating Strategy, Structure, and Rivalry 2. Demand conditions 3. Factor Conditions (both basic and advance) 4. Related and keep Industries And two external factors which influence the factors mentioned above are- 1. Chance 2. Government 2. 2 Firm Structure, Strategy, and Rivalry Our Position in Bangladesh In Bangladesh there are currently a total of 245 companies out of which 200 have operations in the country.The market is totally dominated by the local companies and there are only 5 multi-nationals currently operating. The 245 companies together have5300 brands registered in Ba ngladesh. Among this companies BPL is one of the attractorwith almost 8. 4% of the market destiny. Company (BDT m) Market Size evolution in 2011 Market Share 2010 2011 SPL Pharmaceuticals 15,725. 8 20. 5% 18. 7% 19. 2% Incepta Pharmaceuticals 7,851. 5 28. 6% 9. 3% 9. 0% Beximco Pharmaceuticals 7,415. 0 30. 5% 8. 8% 8. 4% Opsonin Pharma 4,275. 4 27. 2% 5. 1% 4. % Renata 4,076. 8 26. 1% 4. 9% 4. 8% Eskayef Bangladesh 3,980. 3 18. 9% 4. 7% 4. 9% ACI 3,578. 2 24. 9% 4. 3% 4. 2% Acme Pharmaceutical 3,500. 7 13. 7% 4. 2% 4. 5% Aristopharma 3,412. 8 26. 3% 4. 1% 4. 0% dose International 3,070. 2 18. 9% 3. 7% 3. 8% Top 10 Companies 56,886. 5 23. 6% 67. 7% 67. 7% Top 20 Companies 71,382. 5 24. 1% 84. 9% 84. 6% Others Companies 12,661. 6 20. 7% 15. 1% 15. 4% Total Sector 84,044. 1 23. 6% Source World deposit Table 1 Major Players In the Market . 2(a) Company structure BPL gives highest importance to the principles of Co rporate Governance and its implementation within the organization. In BPL we hook up with some rules like 1. All new recruits at BPL undergo a mandatory training on Companys Code of Conduct. 2. From the rattling inception, BPL like the other Strategic Business Units (SBU) ofthe Group maintains and upholds HR policies that are consistent with the LaborLaws of the country. 3. BPL Pharmaceuticals Ltd leads the Group in encouraging workers freedom of connectedness and their right for collective bargaining. . The Company follows laws and encourages a work environment that welcomes novelty and fair treatment in the recruiting process and the workplace. 5. BPL encourages diversity and equal enjoyment fortune in the recruitingprocess and the workplace. 6. The Company pursues policies that proactively address all forms ofdiscriminations in terms of minority, gender and cultural issues. 2. 2(b) Company strategy For years our companys strategy is to capture the maximum dispense done cu stomersatisfaction by quality product. In words we put our strategies in this way 1.In BPL we value, above all, for top quality wellness care products at the least cost reaching the worst rungs of the economic class of pot in the country. 2. We are obliged to our shareholders and strive for protection of their capital as well as ensure highest return and growth of their assets. 3. We try gravely for best compensation to all the employees who constitute the back-bone of the management and operational strength of the Company 4. BPL endeavor for best co-operation of the creditors debtors the banks financial institutions, the suppliers of lancinating material, the providers of utilities-power, feature water etc. nd the customers 5. BPL fulfills her responsibility to the Government by fee of ideal range of due taxes, duties, and claim to various open agencies. 6. We strive, as responsibilities citizen, for a social order of magnitude devoid of malpractices, anti-environment al behaviors, unethical and corruptive dealings. 2. 2. b (1) Long term corporate vision In order to cooperate change magnitude hire in the domestic as well as foreign markets, BPL has undertaken an ambitious expansion program to be spotless in two anatomys. The origin phase, which is already under way, is weared to be completed by 2012at a total cost of BDT 3. billion. We anticipate a 25% cost overrun for a final cost of BDT 4. 5 billion. The first phase is expected to nearly double the current capacity. The second phase will start in 2014, completing in 2017 for a total cost of BDT2. 0 billion (including an estimated cost overrun of 25%). We expect the expansion programs contributing to revenue growth after 2012. We made an presumption that the new plants will operate with an 85% efficiency and after the yearof completion, 25% of the capacity will come on line in each of the following four years. Second phase will also do the same. 2. 2. b(2) Financial conditionBPL Pharmace uticals Ltd (BPL) is one of the two Public Limited Companies of the Group that is listed at the two stock exchanges of Bangladesh. And companys share is considered as Blue Chip at both the stock exchanges. BPL Pharmaceuticals is the stand out market leader with a market share of 19. 3%and domestic revenues of BDT 11. 2 billion in the four billet from April 2009 to expose 2010. Because of its dominating presence throughout the country, BPL has enjoyed steady growth in sales volume. Cost of sales as percentage of sales has also been declining gradually over the year, improving gross margin. . 2(c) Domestic Rivals As we said before BPL Pharmaceuticals stands at number three in terms of market share of 8. 4% and domestic revenues of BDT 8,860. 3 MM in the four quarters from April 2009 to March 2010. BPLs nearest competitors are Incepta Pharmaceuticals and SPL Pharmaceuticals with market shares of 8. 5% and 19. 2% respectively. Incepta and SPL had BDT 4. 9 billion and BDT 11 billion i n domestic sales for the last fourquarters. Although a number of MNCs are operational in Bangladesh, no MNC is among the top ten in terms of domestic sales.Between two top rivals we consider BPL to be our arch rival though their market share is almost half compared to ours but here we have seek to find out there position in the market. Heres market study of BPL If we analyze the present market condition of BPL we can clearly see that it is in a good position. 2. 3 Demand condition In Bangladesh we have huge demand for its products. The demand of local market has helped us to build a starchy customer base and gave us the strength to go for international market. The huge demand of our market leaded us to produce large volume of product.The medicines we are producing now are apt(p) bellow 2. 3(a) Products Category BPL offers a range of pharmaceutical products (400 types of medicine), which include 1. Tablets 2. Capsules 3. Suppositories 4. Injections 5. Liquids 6. Spray, Drops, Oint ment, Cream and disintegrate 7. Oral Dry Powders. 8. Dry Powder Inhalers 9. Metered Dose Inhalers 2. 3(b) Types of Customer By maintaining the quality we set our price conveniently for the mass population ofBangladesh. We never compromise about our drugs quality and so we acquire the thrust ofour customer. 2. 3(c) Present Market statusBesides Bangladesh demand of international market driven us to supply our product in these markets Europe UK Asia Afghanistan, Bhutan, Cambodia, Hong Kong, Iraq, Macau, Malaysia, Myanmar, Nepal, Papua New Guinea, Sri Lanka, Tajikistan, The Philippines, Vietnam, Yemen Africa Comoros Islands, Eritrea, Gambia, Ghana, Kenya, Libya, Malawi, Mauritania, Mauritius, Mozambique, Niger, Rwanda, Sierra Leone, Somalia, Sudan, Tanzania south-central America Belize, Costa Rica, Guatemala And these are the market under there exploration Asia Iran, Iraq, Kuwait, Laos, Maldives, Mongolia, Qatar, Saudi Arabia, Thailand, UAE Africa Algeria, Botswana, Central Afri can Republic, Chad, Ethiopia, Ivory Coast, Nigeria, Rwanda, South Africa South America Jamaica, Chili 2. 3(d) CSR activities Beximco Pharmaceuticals Ltd. is one of the signer of UN Global Compact in Bangladesh. Our CSR activities helped us to increase our demand. Some examples of ouractivities are BPL supports spheric business community to uphold social issues in businessoperations and organism convinced of the benefits which will accrue out of voluntaryadherence to universally recognized social values in transaction of businesses. BPL regularly interacts with the underprivileged segment of the societydirectly or through different NGOs. The Company assists the HIV positive/AIDS patients in gaining better access tomedicine through donation of AIDS medicine to local NGOs. BPL has donated two ambulances to Pabna Municipal Corporation IshwardiMunicipal Corporation for public use. 2. 4 Factors of Endowments (both basic and advance) 2. 4(a) Basic factors Basic factors like natural resources, climate geography human ecology everything is in ourfavor in Bangladesh to produce and provide quality health care. . 4 (b) Advance factors condition In the discussion bellow we tried to describe the advance factors condition of ourcompany at present. 2. 4. b. (1) R and D department Beximco has a strong reverse engineering. It has made a cooperative research agreement with Ciba Specialty Chemicals of Switzerland in proprietary research. In formulation RD, it porees principally on developing new formulations, predominantly through reverse engineering. BPL also focuses on simplifying manufacturing processes and improving cost efficiency.Its growing universe is evident from successful launching of a number of cutting-edge products (for example, Oseltamivir capsules for gentlewoman swine flu treatments, ARVs, anti-cancer products etc. ) forward-looking formulations like multi-layer tablets, sustained release formulations, dispersible tablets, chewable vitamins etc. Wi th considerable experience in MDI formulations, BPLs RD team has successfully developed a range of CFC-free HFA MDIs. In addition, BPL is also developing a number of APIs to ensure availability of raw materials across the range of therapeutic classes.Beximco Pharma has also signed agreements for collaborative research with leading international API manufacturers to strengthen its API pipeline in order to fully capitalize the WTO patent opportunity. 2. 4. b(2) human race recourse Strategic Human Resource Development Programs are the energy sources for BPLHR for running towards the peak of success. BPL employs more than 2,400 staff, including over 300 competent professionals such as pharmacists, chemists, microbiologists, engineers, doctors etc. BPL is the third largest pharmaceutical manufacturing company in Bangladesh with net sales of BDT 4. 7 million, agree to the 2009 annual report. We believe in company growth by increasing efficiency level ofemployees and for that offering e xcellent environment and support for achievement and comeledge up gradation. Our HR department ensures the strong supporting determination to develop & implement HR policy guidelines for ensuring uninterrupted operation and free participation to achieve organizational objective as well as fulfillment of employee needs. maintain an effective way to deal with labor wedding and still no unrest has been recorded as dispute. 2. 4. b(3) Raw materialsWe are proud to say that we are capable of producing raw materials for our own medicines. Some info about our firms potentiality of production is given bellow (a) API unit Established in 1992 and commercial production started in 1995. It is presently the largest quality- heap drugs manufacturer in the country producing international beat bulk pharmaceuticals to satisfy more than hundred pharmaceutical companies throughout the country. b) Factory plants BPL Pharmaceuticals has invested in state of the art formulation plants aline to re gulated market standards.Four plants based on the Dhaka site can producepharmaceutical products to the highest GMP specifications. These four plants are General plant (ap recruitd by MHRA) Cephalosporin plant (quality systems align to MHRA requirements, plant beingprepared for EU regulative agencies and FDA inspections) BFS plant (quality systems aligned to MHRA requirements, plant being prepared for EU regulatory agencies and FDA inspections) Biotech (insulin) plant under construction These plants have been designed by internationally recognized firms and weaponed with the best machines that can currently be found on the European and US markets.BPL Pharmaceuticals has also created quality systems and SOPs according to FDA and EU regulatory agencies specifications 2. 4. b(4) Distribution system It has one of the largest distribution channels in the pharmaceutical industry. The sales force of Beximco, led by a large number of medical representatives, is one of the most aggressi ve among all local manufacturers. This ensures that BPLs products always have a considerably large outreach. 2. 4. b (5) technology Beximco Pharma has always been a groundbreaker in adopting innovative technologies that introduced both sophistication and scale in the business processes.The companys focus on technology is intended to take the company to a standard which would match with other top global generic pharma companies. BPL is the pioneer company from Bangladesh in introducing technology driven (specialty) products in local and international markets. Such specialty products include Inhalation aerosols, including Ozone- propitious HFA MDIs Suppositories Nasal sprays Beximco Pharma has shown its capability in the past by installing state-of-the-art MDI plant and IV fluid plant in collaboration with Pamasol, Switzerland and Pharmaplan, Germany, a sister matter to of Fresenius AG, Germany. 2. Related and supporting industry Related and supporting industries like Hospitals a nd health centers Healthcareprofessionals Insurance and public health bodies Retail pharmacies and stores diagnosticcenters etc are available to support our business firm. In 2006 the total number of hospitals in Bangladesh was 1683. Of these 1683 hospitals, 678 were government hospitals and 1005 were non-governmental 2. 6 The condition of two external factors Chance and Government BPL have enough chance and government support throughout our company life. Theprove of it is the rate of our market share and growth in our country.Though we have some restriction from government about the advertising of our medicine in the media but except that we have our governments full support where we need it. 2. 7 boilersuit analysis of the company position based on porters diamond Why Beximco Pharma is doing well ? The answer lies in the Porters diamond as we can see from our report the entire element that make a successful industries are there in the market. It has strong supporting industries th at help us to stay firmly in its feet. It has got all the factors endowment both basic and advanced.It got a study demand and customer base. And last but not the list its strategies structure is strong enough to face out rivals bluntly. Though we know BPL got strong challenger in the market but the pace they are moving we know we are strong enough to any kind threat no matter from where its coming from. Factors of Endowments (both basic and advanced) Factors of Endowments (both basic and advanced) Related and Supporting Industries Related and Supporting Industries Demand conditions Demand conditions Firm Strategy, Structure, and Rivalry Firm Strategy, Structure, and RivalryLog Frame Intervention Logic Objectively verifiable indicators Source of check Factors of Endowments-Basic Factors-Advanced Factors -communication Distribution System -Skill Labor Human Resource-Research -RnD-Technology -Availability ofNatural resources, climate geography human ecology is in favor. It has one of the biggest distribution systems in Bangladesh. 2,400 staff, including over 300 qualified professionals such as pharmacists, chemists, microbiologists, engineers, doctors etc. Oseltamivir capsules for bird swine flu treatments, ARVs, anti-cancer products etc. advanced formulations like multi-layer tablets, sustained release formulations, dispersible tablets, chewable vitamins etc. Inhalation aerosols, including Ozone benign HFA MDIs Suppositories Nasal sprays-Installing state-of-the-art MDI plant and IV fluid plant in collaboration with Pamasol, Switzerland and Pharmaplan, Germany, a sister concern of Fresenius AG, Germany. World deponeAnnual Report 2011Annual Report 2011Annual Report 2011Annual Report 2011 Firm Structure, Strategy, and Rivalry-Structure-Strategy-Rivalry Corporate Governance -mandatory training on Companys Code of Conduct. BPL like the other Strategic Business Units (SBU-collective bargaining. -diversity and fair treatment in the recruiting process -diversity and equal employment opportunity-Top quality health care products at the least cost reaching the lowest rungs -Highest return and growth of shareholders assets. -Best compensation to all the employees. -Best co-operation of the creditors debtors the banks financial institutions. -Supporting the Government through payment of entire range of due taxes, duties, and claim to various public agencies-Rivalry among existing firms is intense. Incepta Pharmaceuticals and SPL Pharmaceuticals with market shares of 8. 5% and 19. 2% respectively. Annual Report 2011World Bank Demand Condition -Huge demand of local market -large volume of product -Range of pharmaceutical products and 400 types of medicine. -Maintaining the quality setting the price conveniently. Exports Europe UKAsia, Africa, South America World Bank Related And Supportive Industries In 2006 the total number of hospitals in Bangladesh was 1683. Of these 1683 hospitals, 678 were government hospitals and 1005 were non-governmenta l. Wikipedia Chapter 3 Conclusion BPL Pharmaceuticals Ltd, as part of a progressive business group, believes that the advancement of good health occurs not only through the innovation, production and distribution of its products, but also through the creation and preservation of a healthy environment. Transparency is a nub value of BPL Pharmaceuticals Ltd and otherSBUs of the Group and is strictly followed at every timber of the business process. BPL Pharmaceuticals Limited has extended her range of services towards the highway of global market.We believe the way we are leading towards our goal soon we will be known as one of the top leading pharmaceutical company on the world 3. 2 Recommendations After analyze the wholly report we can recommend that We have to give more ferocity on the technological support to compete in global market because after 2016 the TRIPS agreement will expire. Should pursue the government to established exportation cell to promote export ofpharmaceu ticals to grab and capitalized the huge export opportunity in LDCs. RD activities of the company have to be ameliorate if it wants to compete with global players. Patent Law, which is valid up to 2016 for Least highly-developed Countries like Bangladesh. After 2016 the advantage enjoyed by Bangladesh will evaporate so to face that condition we have to prepare our selves. Though we have our own API plant still we have to import the API equipmentsbut we should try to produce our own API requirement. 3. 3 References We used these references to prepare our study International Business by Charles W. L. Hill www. BPLpharma. com. bd www. beximco pharma . com .World bank